Clinical trial
Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy.
NCT03091127 is registered in ClinicalTrials.gov with Amgen as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe Who Have Received at Least One Prior Therapy.
- Lead sponsor
- Amgen
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 14, 2017
- Completion date
- March 17, 2020
- Enrollment
- 705 (actual)
- Sites
- 114
Conditions
As the registry lists them; a condition with its own page is linked.